Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy

31 July 2021 : Clinical Research

Xingqin Zhou^1BCE, Yazhou Chang^2BD, Jing Qian^1BF, Chaoyan Shen^1DEF, Jie Han^1EF, Hongyu Zhao^1DF, Renan Chang^3AG*

DOI: 10.12659/MSM.929474

Med Sci Monit 2021; 27:e929474

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Area under the curve of 5-Fluorouracil concentration in blood (actual exposure) in every cycle.

	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6
N	54	54	50	47	44	40
Mean	19.3	21.9	24.8	26.3	26.3	26.8
SD	8.2	7.5	6.4	5.9	5.5	5.2
Median	17	23	24.5	28	26	26.5
Range	7–37	9–41	13–36	14–38	16–37	17–38
CV	42.4%	34.2%	25.7%	22.4%	21.0%	19.4%
AUC ≤19	32	22	11	7	4	4
AUC ≤19	57.4%	40.7%	22.0%	14.9%	9.1%	10.0%
AUC 20–29	16	23	24	22	28	24
AUC 20–29	29.6%	42.6%	48.0%	46.8%	63.6%	60.0%
AUC ≥30	7	9	15	18	12	12
AUC ≥30	13.0%	16.7%	30.0%	38.3%	27.3%	30.0%

Back to the Article